The University of Oxford in the United Kingdom said today that the 2019 coronavirus disease (COVID-19) vaccine developed jointly with AstraZeneca was found to have the best immune response with two full doses after additional trials.
The results of the late-stage clinical trial announced by AstraZeneca on Nov. 23 showed that the protective power of administering two full doses of the vaccine was even lower than the abnormal phenomenon of halving the first dose and the second full dose, and although the overall protective power had a 70% effect, Oxford/AstraZeneca still decided to do additional trials.
Reuters reports that the results announced this time are from a new combined Phase 1/Phase 2 trial, but there is no mention of the previously curious pattern of half of the first dose and full dose of the second dose.
The additional trial announced today is also a two-dose vaccination model, with the first full dose, the second half of the dose, and both full doses, respectively. The Oxford vaccine trial program originally planned only two doses of the trial model.
Oxford University said in a statement today, “The study showed that the effect of two doses of vaccination was better than just one, regardless of the mode; the standard mode of two full doses produced the best immune response. The trial showed that the vaccine stimulates the full range of antibody and T-cell function.”
Recent Comments